<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhang C</submitter><funding>The Science and Technology Research and Development Program of Shaanxi Province, China</funding><funding>Chinese Postdoctoral Science Foundation, China</funding><funding>Basic Research Program Youth Project of Shanxi Province, China</funding><funding>National Natural Science Foundation of China</funding><pagination>1868</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12706891</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>25(1)</volume><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Papillary thyroid carcinoma (PTC) is a significant type of endocrine cancer, characterized by diverse genetic alterations and a complex molecular environment. Extracellular vesicles (EVs), especially those derived from mesenchymal stem cells (MSCs), have emerged as promising targeted drug carriers for cancer cells. Additionally, reprogramming MSC-derived EVs represents a novel strategy for cancer gene therapy, offering potential solutions to clinical challenges and new treatment directions. Increasing evidence suggests that MSC-derived EVs play a crucial role in tumor progression by delivering circular RNAs (circRNAs), which function as microRNA (miRNA) sponges. However, the underlying molecular mechanisms and their clinical applications remain to be fully explored and</pubmed_abstract><journal>BMC cancer</journal><pubmed_title>Engineered hUCMSC-derived extracellular vesicles deliver circ-0000258 to restore p53-mediated tumor suppression in papillary thyroid carcinoma.</pubmed_title><pmcid>PMC12706891</pmcid><funding_grant_id>202203021222371</funding_grant_id><funding_grant_id>2022JQ-881</funding_grant_id><funding_grant_id>2022M712590</funding_grant_id><funding_grant_id>82200386</funding_grant_id><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Yu B</pubmed_authors><pubmed_authors>Li S</pubmed_authors><pubmed_authors>Zhang C</pubmed_authors><pubmed_authors>Li L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Engineered hUCMSC-derived extracellular vesicles deliver circ-0000258 to restore p53-mediated tumor suppression in papillary thyroid carcinoma.</name><description>&lt;h4>Introduction&lt;/h4>Papillary thyroid carcinoma (PTC) is a significant type of endocrine cancer, characterized by diverse genetic alterations and a complex molecular environment. Extracellular vesicles (EVs), especially those derived from mesenchymal stem cells (MSCs), have emerged as promising targeted drug carriers for cancer cells. Additionally, reprogramming MSC-derived EVs represents a novel strategy for cancer gene therapy, offering potential solutions to clinical challenges and new treatment directions. Increasing evidence suggests that MSC-derived EVs play a crucial role in tumor progression by delivering circular RNAs (circRNAs), which function as microRNA (miRNA) sponges. However, the underlying molecular mechanisms and their clinical applications remain to be fully explored and</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-06T04:05:05.542Z</modification><creation>2026-05-25T03:12:06.991Z</creation></dates><accession>S-EPMC12706891</accession><cross_references><pubmed>41398660</pubmed><doi>10.1186/s12885-025-15230-5</doi></cross_references></HashMap>